AKERS - Heparin, Asthma, Diabetes, Lung Cancer - Huge Potential.
Penny told Citywire: ‘There is enough there to make this exciting. They have some products with big potential and are funded for the next 12 months.
Penny tips the Heparin allergy testing product to bring in near-term cash. Indeed, it could be the 'game changer', he says.
Another potential winner is Akers’ breath test for diabetes and the company has now had modest success selling some of the products into emerging markets.
At its update last month, chief executive Thomas A. Nicolette revealed that sales of its commercialised diagnostic products has far exceeded market expectations in the year to the end of December 2010, adding that the group had received its first product order from Al Tadawi Medical in the Middle East for its Tri-Cholesterol check tests.
The deal boosted revenues by some $1.5million. More good news came from the Heparin PF4 test, which produced revenue growth of 37% higher year on year.
Disclaimer:
As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. The author may own shares in any companies discussed, all opinions are his/her own & are general/impersonal. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.
Akers Biosciences, Inc. (ABI) is focused on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s main product is a disposable breathalyzer test that measures the blood alcohol content of the user. ABI’s portfolio is derived from four of the Company’s six platform technologies: Particle ImmunoFiltration Assay (PIFA), Micro Particle Catalyzed (MPC) Biosensor, Rapid Enzymatic Assay (REA) and Synthetic Macrocycle Complex (SMC). The core products marketed under the PIFA platform are the PIFA Heparin/PF4 Rapid Assay, a variety of rapid infectious disease screening tests, and the Battlefield Blood Transfusion Card. more »
6 Posts on this Thread show/hide all
BUYOUT?
Penny told Citywire: ‘Diagnostics is an attractive area. When you get the science right you can get very high margins. If this does not work, the company will need to secure more money but it now has time to bring out further products.’
And he has form in getting this area right. Penny has held a number of diagnostics peers including Immuno-Diagnostics Systems which floated at 75p and reached £9 after it successfully developed and commercialised its products.
He also held BBI, which was eventually bought out at a premium by larger US rival Inverness Medical, as well as EKF and Tepnel Life Sciences, which were also bought out.
Penny expects Akers to add 10-12 to its sales force to complement the one highly successful person already in place, but even if the selling does not lead to as many orders as he would like, Penny says there are plenty of others out there, such as EKF, who have the management expertise and track record to distribute such products.
Further share price uplift could also come in the form of a buyout, from a larger rival bioscience peer.
In reply to shareshark23, post #1
My first question on reading this was frankly, who's Penny?
It might be more helpful if you included the link to the original Citywire article.
http://citywire.co.uk/wealth-manager/shrewdie-why-medical-minnow-akers-could-be-a-gem/a472877/2
This price is very cheap guys. Brittany Ivestments sold their stake in a distressed way as the fund was in trouble and needed its cash. it took the price down with it of AKR but nothing to do with how AKR is doing. The company had support at a 4p share placing etc and is set to release its best results to date at the beginning of April, plus todays good news on the Patent today. We could see this upwards of 8-10p very easily.
NEW BUY RATING! - 10P
16 MAR 2011 Akers Biosciences* AKR (FTSE AIM All Share) 3p BUY (TP - 10p)
Company: Daniel Stewart
New Patent
?? Akers Biosciences (ABI) was granted patent protection in the United States for its novel blood cell separator technology.
?? The technology enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples; serum or plasma samples are extracted within minutes and are then ready for immediate analysis by rapid assay devices.
?? The technology forms a key element of the company's PIFA POC test—the point-of-care extension of ABI's heparin platelet factor 4 rapid assay. It can also be used in many other diagnostic tests, transforming them from clinical laboratory assays into point-of-care tests.
?? Conventional methods of blood cell separation are labour-intensive and time consuming, typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialised equipment.
Nice chart...
should be a lot higher than this price. the seller is now out of the way and things could shoot up rapidly. there sales are 85% higher than last year and resluts are out wekk of 11th April so expect heavy buying until then!